CA-MOVIUS
22.9.2020 17:02:11 CEST | Business Wire | Press release
Movius , the leading global provider of mobile unified communication software, is now enabling enterprises to securely and compliantly communicate with clients on their preferred mobile messaging channel. Today, the company announced the integration of WhatsApp support from within Movius MultiLine, their secure mobile communication service that can be deployed over any smartphone device on any global carrier. The integration will help unify and capture all business voice and messaging channels through a single integrated user experience, while enabling firms to effortlessly meet regulatory and surveillance needs.
An open Beta for this integration is available now and general availability is expected in the fourth quarter, 2020. As users continue to work remotely, they will find the expanded enterprise service provides unmatched productivity anywhere – and compliance everywhere – especially as companies accelerate their emerging Bring Your Own Device (BYOD) strategies and implementations.
WhatsApp users will experience a single, global solution that auto-archives in accordance with regulation and surveillance protocols – improving customer engagement for users, while simultaneously putting to rest any compliance gap concerns for the enterprise. This expansion of the MultiLine service, which integrates messaging, voice and compliance into enterprise workflows, lets Movius users leverage existing communications preferences and increase productivity – no matter where they are.
As digital transformation continues to accelerate, customers are quickly adapting to new mobile channels and expect the solutions that support them to do the same. With the rising popularity of services like WhatsApp – with two billion users worldwide – firms run the risk of unsanctioned use from their employees as they interact with clients. Or, by sanctioning a “no WhatsApp policy,” they risk alienating customers that prefer WhatsApp as their way to connect. Not only can data become unsafe when WhatsApp is used on personal devices, but the encryption makes it difficult to monitor and supervise activity, a necessary record-keeping oversight for regulated industries.
“We see this as an opportunity for enterprises to effectively leverage the business side of WhatsApp, endeavoring to bring that form of communication in the realm of compliance, supervision and client affinity, rather than banning and restricting the use of a popular way to connect,” said Movius Chief Product and Technology Officer, Amit Modi. “This is how enterprises are communicating and what their clients are demanding, and we stand by our mission to provide enterprises with compliant, reliable mobile communications that enable employees to communicate with clients whether they are sitting desk side or working remotely.”
With this integration, customers can engage with voice, text and WhatsApp all through a single interface, while allowing firms to have complete ownership and visibility into business conversations. Bringing these forms of communication into one place also allows for complete separation of business and personal correspondence among BYOD users, allowing firms to ensure their business data is protected and employees’ personal data remains private and untouched.
To learn more and request Beta access, click here: www.moviuscorp.com/whatsapp . Interested parties can also join webinars on the WhatsApp integration starting October 6; learn more about those here: https://moviuscorp.com/product-webinar-introducing-movius-whatsapp-messaging-connector/ .
About Movius
Movius is the leading global provider of mobile unified communications for the new world of work, offering productivity anywhere and compliance everywhere. Movius software and services integrate messaging, voice and compliance into enterprise workflows which helps organizations like JP Morgan Chase & Co, UBS, Jefferies, BCG Partners and Cantor Fitzgerald deliver better engagement for their clients. Enterprises around the world use the company’s all-in-one mobility platform to connect with their customers in more convenient, cost-effective and compliant ways.
The platform offers an easy way to extend and integrate voice, text, and messaging services into other systems, like CRM or collaboration tools. Movius recently released several new product capabilities, including WhatsApp support and integration with Salesforce CRM. These capabilities deliver additional customer value and can elevate the role MultiLine plays in customer organizations.
Headquartered in Atlanta, Movius has additional locations in Silicon Valley, Calif., and Bangalore, India. Movius works with leading global partners like T-Mobile, BlackBerry, BT Global, Telstra, and Telefónica. For more information on Movius, visit https://www.moviuscorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005730/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom